Camp4 Therapeutics Corp. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Camp4 Therapeutics Corp. (Nasdaq: CAMP) is a clinical-stage biopharmaceutical company developing RNA-based therapeutics designed to upregulate gene expression to treat genetic diseases. The company utilizes its proprietary RNA Actuating Platform (RAP Platform) to identify regulatory RNAs (regRNAs) and generate antisense oligonucleotide (ASO) candidates. This report covers the fiscal year ended December 31, 2024. The company completed its Initial Public Offering (IPO) on October 15, 2024, and converted all outstanding convertible preferred stock to common stock.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0.7 million | $0.4 million |
| Net Loss | $(51.8) million | $(49.3) million |
| Accumulated Deficit | $(211.8) million | $(159.9) million |
| Cash and Cash Equivalents (Year-End) | $64.0 million | $38.4 million |
| Net Cash Used in Operating Activities | $(45.6) million | $(44.2) million |
| Net Cash Provided by Financing Activities | $71.7 million | $0.3 million |
Note: The company has no products approved for sale and has not generated revenue from product sales. Revenue consists of collaboration and license fees.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased by $0.3 million (86%) primarily due to $0.7 million recognized from a new collaboration agreement with BioMarin Pharmaceutical Inc. signed in September 2024, compared to $0.4 million from a license agreement with Fulcrum Therapeutics in 2023.
- Operating Expenses: Total operating expenses increased by $1.5 million to $53.7 million. General and Administrative (G&A) expenses rose by $3.3 million, driven by increased personnel costs (including stock-based compensation) and professional fees associated with the IPO and public company compliance. Research and Development (R&D) expenses decreased by $1.8 million due to fewer external preclinical activities, partially offset by increased clinical trial costs for the lead candidate.
- Liquidity: Cash balances increased significantly following the IPO, which generated net proceeds of approximately $72.4 million. The company now has sufficient cash to fund operations into the second quarter of 2026.
- Capital Structure: All convertible preferred stock was converted to common stock upon the IPO closing. The company now has 20.2 million shares of common stock outstanding.
Guidance, Outlook, and Risks
Outlook and Milestones:
- CMP-CPS-001 (Lead Candidate): Currently in a Phase 1 clinical trial in healthy volunteers in Australia. The company expects to report data from the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) portions of the trial in the fourth quarter of 2025. A Phase 1b expansion to enroll female OTC heterozygotes is planned for the second quarter of 2025.
- CMP-SYNGAP-01: A development candidate for SYNGAP1-related disorders. Good Laboratory Practice (GLP) toxicology studies are expected to initiate in 2025.
- GBA1 Program: Discovery program for Parkinson's disease is ongoing.
Going Concern Warning: The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for substantial additional capital to fund operations beyond the current cash runway. Management estimates current cash will last into Q2 2026, but future funding requirements are uncertain.
Key Risks:
- Capital Requirements: Failure to raise additional capital could force the company to delay, limit, or terminate development programs.
- Clinical Development: High risk of failure in clinical trials; preclinical data may not predict clinical success. The Phase 1 trial uses a ureagenesis rate test (URT) which is not an established clinical endpoint.
- Third-Party Dependence: Reliance on third-party manufacturers, including suppliers in China (e.g., WuXi AppTec), which may be subject to trade restrictions or sanctions (e.g., BIOSECURE Act).
- Intellectual Property: The company does not currently own or in-license any issued patents directed to the composition of matter of its product candidates.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the management estimate that cash will last into Q2 2026 and assess the likelihood of securing additional financing before that date.
- Phase 1 Trial Design: Review the clinical trial protocol for CMP-CPS-001, specifically the reliance on the Ureagenesis Rate Test (URT) as a pharmacodynamic biomarker and its correlation to clinical efficacy in patients.
- Supply Chain Risks: Investigate the company's contingency plans regarding its reliance on Chinese suppliers for raw materials in light of potential U.S. trade restrictions (BIOSECURE Act).
- Patent Portfolio: Confirm the status of pending patent applications for composition of matter, given the current lack of issued patents for product candidates.
- BioMarin Collaboration: Review the terms of the BioMarin agreement, specifically the $1.0 million upfront payment and the potential for future milestones totaling up to $185 million per program.